Peptide Price Finder

Home · Research · Skin, hair & tanning

Vialox research

What published studies found for Vialox: 3 papers, 0 in humans, with sample sizes and key results.

D
Little or no evidence
Why: Only two computer-modelling and cell-culture studies; no animal or human data.

Vialox (pentapeptide-3, Gly-Pro-Arg-Pro-Ala) has no published human trials. The only direct studies are two 2026 computer-modelling plus cell-culture papers, and reviews note that 'botox-like' cosmetic peptides rely mainly on laboratory rather than clinical data.

? 3 inconclusive

No human safety or efficacy data for Vialox in the published literature.

Browse and filter these papersVialox prices and vendors

Reviews

? InconclusivereviewFacial Plast Surg · 2026

Peptides in Facial Plastic Surgery: Emerging Applications in Aesthetics and Rejuvenation.

No new dataNarrative review for facial plastic surgery practice

Review of cosmetic peptides including neurotransmitter-inhibiting 'botox-like' peptides: most evidence is from in vitro and ex vivo studies, with limited regulatory oversight and few randomized trials.

Studied
Cosmetic and signal peptides including neurotransmitter-inhibiting 'botox-like' peptides
Main outcome
Evidence, mechanisms, safety and efficacy of peptides in skincare
Authors' conclusion
Most supporting evidence comes from in vitro and ex vivo studies rather than randomized clinical trials, and products have limited regulatory oversight.
Limitations
Narrative review with no original data; Vialox not individually assessed in the abstract.
PubMed 41839222DOI

Animal & lab studies

? Inconclusivein vitroChem Biodivers · 2026

Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl Pentapeptides for Antiaging Applications.

Cells / labMolecular docking, molecular dynamics, ADME/toxicity prediction and in vitro cytotoxicity assay of Vialox and Leuphasyl

Docking and molecular-dynamics models suggested Vialox interacts with SIRT-1 (and less with MMPs); it was not cytotoxic to HaCaT skin cells up to 1 mg/mL. No skin-effect measurements in people or animals.

Key resultNeither peptide showed cytotoxicity on HaCaT cells at concentrations up to 1 mg/mL
Studied
Computer models and HaCaT keratinocyte cell line
Compared with
Leuphasyl
Main outcome
Predicted binding to MMP-1, -8, -13 and SIRT-1; cytotoxicity
Authors' conclusion
Docking suggested Vialox preferentially targets SIRT-1 and Leuphasyl MMP-13; the authors consider this mechanistic insight supporting their promise as dermocosmetic agents.
Limitations
In silico and cytotoxicity only; no skin-effect measurements in people or animals.
PubMed 42116636DOIFree full text
? Inconclusivein vitroCell Biochem Biophys · 2026

In Vitro and In Silico Assessment of Anticancer Activity of Venom-Derived and Biomimetic Neurotransmitter Inhibitor Pentapeptides.

Cells / labMolecular docking, MM-GBSA, molecular dynamics, ADMET analysis and MTT cell assays of Vialox and Leuphasyl

Computer models predicted binding of Vialox to cancer targets (e.g. EGFR, PI3K), and it was cytotoxic to some cancer cell lines (MDA-MB-231, PC3) in MTT assays; not related to its cosmetic use.

Key resultDocking scores -10.63 to -7.59 kcal/mol; Vialox-EGFR -9.24 kcal/mol and MM-GBSA binding energy -65.29 kcal/mol; most cytotoxic in MDA-MB-231 and PC3 cells
Studied
Computer models and cancer cell lines (including MDA-MB-231 and PC3)
Compared with
Leuphasyl
Main outcome
Binding to oncogenic targets (EGFR, PI3K) and cytotoxicity
Authors' conclusion
The findings suggest both peptides may exhibit selective anticancer effects; ADMET predicted limited oral bioavailability and minimal BBB penetration.
Limitations
In silico and cell-line data only; unrelated to Vialox's cosmetic use.
PubMed 42412310DOI

Verdicts are judged on each paper's own main outcome; grades run from A (strong human evidence) to D (little or none). Details are read from the abstracts, and figures are reproduced only from openly licensed full texts. Not medical advice.